Glenmark receives USFDA approval for Generic Diabetes Drug

Glenmark Life Sciences announces Rs. 22.50 interim dividend

Glenmark Receives USFDA Approval for Generic Diabetes Drug

Glenmark Pharmaceuticals said on Tuesday that it has received clearance from the prestigious US Food & Drug Administration (US FDA) to introduce a generic diabetic medication in the American market, which is a significant step.

The drug in question is called Saxagliptin Tablets, and it comes in 2.5 mg and 5 mg strengths. The famed Onglyza1 pills from AstraZeneca are quite similar to this generic variant. According to their official news statement, Mumbai-based Glenmark is overjoyed to have gotten the product’s final FDA clearance.

Onglyza tablets (2.5 mg and 5 mg) demonstrated extraordinary performance, according to trustworthy IQVIATM sales statistics, and achieved an excellent annual sales figure of almost USD 100.7 million over the 12-month period that ended in June 2023.

With this most recent certification, Glenmark’s portfolio dramatically grows and now boasts an astounding total of 184 goods that are approved for distribution in the US market. The business is also committed to providing the public with high-quality pharmaceutical solutions as seen by the 49 abbreviated new drug applications (ANDAs) that are now waiting for FDA clearance.

About Glenmark:

Glenmark Pharmaceuticals Inc functions as a pharmaceutical company, providing a range of safe, cost-effective, and high-quality medications. With a global presence, Glenmark Pharmaceuticals serves communities around the world.

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *